Hepatorenal Syndrome Treatment Market – Global Industry Analysis and Forecast (2023-2029)


Hepatorenal Syndrome Treatment Market is expected to reach US$ 13.73 Bn. at a CAGR of 13.12% during the forecast period 2029.

Hepatorenal Syndrome Treatment Market Overview:

Hepatorenal syndrome (HRS) is a life-threatening medical disorder in which kidney function rapidly deteriorates in those who have cirrhosis or fulminant liver failure. Unless a liver transplant is performed, HRS is usually deadly, while other therapies, such as dialysis, might slow the progression of the disease.Hepatorenal Syndrome Treatment Market To know about the Research Methodology:- Request Free Sample Report

Hepatorenal Syndrome Treatment Market Dynamics:

Rising prevalence of Hepatorenal Syndrome is the major factor contributing to the market growth.

The rise in the number of individuals with liver injury or cirrhosis is the key driver of the Global Hepatorenal Syndrome Treatment market. According to data from the Centres for Disease Control and Prevention, 4.5 million persons in the United States were diagnosed with chronic liver disease in 2022. Patients with Hepatorenal syndrome typically have a wide range of symptoms, including abdominal pain, weakness, and discomfort. Severe symptoms include a jaundice-like yellowing of the skin and eyes, an enlarged liver and spleen, and fluid collection in the abdomen known as ascites.

To improve the market, increased illness knowledge and patient support initiatives are needed. Governments in both rich and developing nations run public awareness efforts to urge people to seek early diagnosis of kidney and liver illness, lowering death and morbidity rates. Increasing the number of fast-track and orphan medication designations also helps to boost the market growth. BioVie Inc. announced in November 2018 that the FDA had granted its Terlipressin medication Orphan Drug Designation for the treatment of hepatorenal syndrome (HRS). Another element driving market growth is the rising consumption of harmful foods and beverages, such as alcohol. The rising elderly population, as well as the occurrence of disease, boosts the market growth. Albumin's widespread use is also aiding the market's growth. Healthcare professionals propose a combination of albumin combined with antibiotics as a cost-effective treatment for HRS with cirrhosis. The treatment of HRS, on the other hand, has been shown to put an individual under extreme financial stress, hence impeding the market growth.

The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Hepatorenal Syndrome Treatment Market Segment Analysis:

The Hepatorenal Syndrome Treatment Market is segmented on the basis of Treatment and End-Users.

Based on Treatment, the therapeutics segment is expected to grow at a CAGR of XX% during the forecast period. Patients prefer taking pharmaceuticals over having procedures, thus the therapeutics segment is likely to increase at a faster rate. Increasing the number of medications with fast track and orphan designations is also helping to grow the market. Several pharmaceuticals have been designated as orphan pharmaceuticals, which accelerate their approval process, and this could be a driver driving treatment growth. The FDA granted Orphan Medication designation to BioVie Inc.'s Terlipressin drug for the treatment of hepatorenal syndrome in November 2018. Orphan medication status entitles manufacturers to a variety of benefits, including tax rebates for eligible clinical trials and seven years of commercial exclusivity following regulatory approval. This will drive the global market during the forecast period.

Hepatorenal Syndrome Treatment Market Regional Insights:

North America dominates the global market.

Throughout the projected period, North America is likely to lead the global market. Factors such as the existence of important companies developed healthcare infrastructure, and the growing prevalence of severe liver disease and cirrhosis are some of the important factors responsible for the market's big share. Furthermore, favorable government efforts and an increase in the number of research partnerships are projected to propel the market forward. Due to favorable healthcare legislation, a large number of patients, and a developed healthcare market, the United States have the largest share in this region. Cirrhosis affects one in every 400 adults in the United States, according to the US Department of Health and Human Services. According to statistics, the region's market growth is boosted by an expanding patient pool and rising disposable income.

The report also helps in understanding Global Hepatorenal Syndrome Treatment Market dynamics, structure by analyzing the market segments and project the Global Hepatorenal Syndrome Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Hepatorenal Syndrome Treatment Market make the report investor’s guide.

Hepatorenal Syndrome Treatment Market Scope: Inquire before buying






Global Hepatorenal Syndrome Treatment Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US$ 5.79 Bn.




Forecast Period 2023 to 2029 CAGR:
13.12%
Market Size in 2029:
US$ 13.73 Bn.




 Segments Covered:
by Treatment
Therapeutics
Liver Transplantation
Renal Replacement Therapy
Other Treatments




by End-users
Hospitals
Ambulatory Surgical Centers
Academic and Research Institutes
Others






Hepatorenal Syndrome Treatment Market, by Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Hepatorenal Syndrome Treatment Market, Key players:

1.Cumberland Pharmaceuticals, Inc.
2.Orphan Therapeutics, LLC.
3.BioVie Inc.
4.Mallinckrodt Pharmaceuticals
5.Ikaria Inc.
6.ESP Pharma Inc.
7.Edwards Lifesciences Corporation
8.Becton, Dickinson and Company
9.Fuji Systems Corp.
10.Johnson & Johnson Co.
11.New Medicon Pharma Lab
12.La Jolla Pharmaceutical Company
13.Noorik Biopharmaceuticals
14.PharmaIN Corp
15.Hikma Pharmaceuticals plc

Frequently Asked Questions:

1. Which region has the largest share in Global Hepatorenal Syndrome Treatment Market?
Ans: North America region holds the highest share in 2022.

2. What is the growth rate of Global Hepatorenal Syndrome Treatment Market?
Ans: The Global market is growing at a CAGR of 13.12% during forecasting period 2023-2029.

3. What is scope of the Global Hepatorenal Syndrome Treatment market report?
Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Hepatorenal Syndrome Treatment market?
Ans: The important key players in the Global market are – Cumberland Pharmaceuticals, Inc., Orphan Therapeutics, LLC., BioVie Inc., Mallinckrodt Pharmaceuticals, Ikaria Inc., ESP Pharma Inc., Edwards Lifesciences Corporation, Becton, Dickinson and Company, Fuji Systems Corp., Johnson & Johnson Co., New Medicon Pharma Lab, La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals, PharmaIN Corp, Hikma Pharmaceuticals plc, and.

5. What is the study period of this market?
Ans: The Global market is studied from 2022 to 2029. 




1. Preface
1.1. Market Definition and Key Research Objectives
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Hepatorenal Syndrome Treatment Market Size, by Market Value (US$ Mn)
3.1. Global Market Segmentation
3.2. Global Market Segmentation Share Analysis, 2021
3.2.1. Global
3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
3.3. Geographical Snapshot of the Hepatorenal Syndrome Treatment Market
3.4. Geographical Snapshot of the Hepatorenal Syndrome Treatment Market, By Manufacturer share
4. Global Hepatorenal Syndrome Treatment Market Overview, 2022-2029
4.1. Market Dynamics
4.1.1. Drivers
4.1.1.1. Global
4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.2. Restraints
4.1.2.1. Global
4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.3. Opportunities
4.1.3.1. Global
4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.4. Challenges
4.1.4.1. Global
4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.5. Industry Trends and Emerging Technologies
4.1.6. Porters Five Forces Analysis
4.1.6.1. Threat of New Entrants
4.1.6.2. Bargaining Power of Buyers/Consumers
4.1.6.3. Bargaining Power of Suppliers
4.1.6.4. Threat of Substitute Products
4.1.6.5. Intensity of Competitive Rivalry
4.1.7. Value Chain Analysis
4.1.8. Technological Roadmap
4.1.9. Regulatory landscape
4.1.10. Impact of the Covid-19 Pandemic on the Global Hepatorenal Syndrome Treatment Market
5. Supply Side and Demand Side Indicators
6. Global Hepatorenal Syndrome Treatment Market Analysis and Forecast, 2022-2029
6.1. Global Hepatorenal Syndrome Treatment Market Size & Y-o-Y Growth Analysis.
7. Global Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
7.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
7.1.1. Therapeutics
7.1.2. Liver Transplantation
7.1.3. Renal Replacement Therapy
7.1.4. Other Treatments
7.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
7.2.1. Hospitals
7.2.2. Ambulatory Surgical Centers
7.2.3. Academic and Research Institutes
7.2.4. Others
8. Global Hepatorenal Syndrome Treatment Market Analysis and Forecasts, By Region
8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029
8.1.1. North America
8.1.2. Europe
8.1.3. Asia-Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9. North America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
9.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
9.1.1. Therapeutics
9.1.2. Liver Transplantation
9.1.3. Renal Replacement Therapy
9.1.4. Other Treatments
9.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
9.2.1. Hospitals
9.2.2. Ambulatory Surgical Centers
9.2.3. Academic and Research Institutes
9.2.4. Others
10. North America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, By Country
10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
10.1.1. US
10.1.2. Canada
10.1.3. Mexico
11. U.S. Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
11.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
11.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
12. Canada Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
12.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
12.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
13. Mexico Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
13.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
13.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
14. Europe Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
14.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
14.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
15. Europe Hepatorenal Syndrome Treatment Market Analysis and Forecasts, By Country
15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
15.1.1. U.K
15.1.2. France
15.1.3. Germany
15.1.4. Italy
15.1.5. Spain
15.1.6. Sweden
15.1.7. CIS Countries
15.1.8. Rest of Europe
16. U.K. Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
16.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
16.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
17. France Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
17.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
17.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
18. Germany Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
18.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
18.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
19. Italy Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
19.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
19.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
20. Spain Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
20.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
20.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
21. Sweden Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
21.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
21.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
22. CIS Countries Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
22.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
22.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
23. Rest of Europe Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
23.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
23.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
24. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
24.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
24.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
25. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis and Forecasts, by Country
25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
25.1.1. China
25.1.2. India
25.1.3. Japan
25.1.4. South Korea
25.1.5. Australia
25.1.6. ASEAN
25.1.7. Rest of Asia Pacific
26. China Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
26.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
26.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
27. India Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
27.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
27.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
28. Japan Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
28.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
28.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
29. South Korea Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
29.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
29.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
30. Australia Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
30.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
30.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
31. ASEAN Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
31.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
31.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
32. Rest of Asia Pacific Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
32.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
32.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
33. Middle East Africa Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
33.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
33.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
34. Middle East Africa Hepatorenal Syndrome Treatment Market Analysis and Forecasts, by Country
34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029
34.1.1. South Africa
34.1.2. GCC Countries
34.1.3. Egypt
34.1.4. Nigeria
34.1.5. Rest of ME&A
35. South Africa Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
35.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
35.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
36. GCC Countries Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
36.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
36.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
37. Egypt Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
37.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
37.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
38. Nigeria Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
38.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
38.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
39. Rest of ME&A Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
39.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
39.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
40. South America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
40.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
40.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
41. South America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, by Country
41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029
41.1.1. Brazil
41.1.2. Argentina
41.1.3. Rest of South America
42. Brazil Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
42.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
42.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
43. Argentina Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
43.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
43.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
44. Rest of South America Hepatorenal Syndrome Treatment Market Analysis and Forecasts, 2022-2029
44.1. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
44.2. Market Size (Value) Estimates & Forecast By End users, 2022-2029
45. Competitive Landscape
45.1. Geographic Footprint of Major Players in the Global Hepatorenal Syndrome Treatment Market
45.2. Competition Matrix
45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment
45.2.2. New Product Launches and Product Enhancements
45.2.3. Market Consolidation
45.2.3.1. M&A by Regions, Investment and Verticals
45.2.3.2. M&A, Forward Integration and Backward
Integration
45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
45.3. Company Profile : Key Players
45.3.1. Cumberland Pharmaceuticals, Inc.
45.3.1.1. Company Overview
45.3.1.2. Financial Overview
45.3.1.3. Geographic Footprint
45.3.1.4. Product Portfolio
45.3.1.5. Business Strategy
45.3.1.6. Recent Developments
45.3.2. Orphan Therapeutics, LLC.
45.3.3. BioVie Inc.
45.3.4. Mallinckrodt Pharmaceuticals
45.3.5. Ikaria Inc.
45.3.6. ESP Pharma Inc.
45.3.7. Edwards Lifesciences Corporation
45.3.8. Becton, Dickinson and Company
45.3.9. Fuji Systems Corp.
45.3.10. Johnson & Johnson Co.
45.3.11. New Medicon Pharma Lab
45.3.12. La Jolla Pharmaceutical Company
45.3.13. Noorik Biopharmaceuticals
45.3.14. PharmaIN Corp
45.3.15. Hikma Pharmaceuticals plc
46. Primary Key Insights
  • INQUIRE BEFORE BUYING